- Home
- VRDN vs INMD Comparison
VRDN vs INMD Comparison
Compare VRDN & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- INMD
- Stock Information
- Founded
- VRDN 2006
- INMD 2008
- Country
- VRDN United States
- INMD Israel
- Employees
- VRDN N/A
- INMD N/A
- Industry
- VRDN Medical Specialities
- INMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- VRDN Health Care
- INMD Health Care
- Exchange
- VRDN Nasdaq
- INMD Nasdaq
- Market Cap
- VRDN 1.5B
- INMD 1.4B
- IPO Year
- VRDN N/A
- INMD 2019
- Fundamental
- Price
- VRDN $20.14
- INMD $18.01
- Analyst Decision
- VRDN Strong Buy
- INMD Buy
- Analyst Count
- VRDN 10
- INMD 6
- Target Price
- VRDN $37.25
- INMD $22.60
- AVG Volume (30 Days)
- VRDN 1.1M
- INMD 1.1M
- Earning Date
- VRDN 11-12-2024
- INMD 10-30-2024
- Dividend Yield
- VRDN N/A
- INMD N/A
- EPS Growth
- VRDN N/A
- INMD N/A
- EPS
- VRDN N/A
- INMD 1.84
- Revenue
- VRDN $302,000.00
- INMD $423,746,000.00
- Revenue This Year
- VRDN N/A
- INMD N/A
- Revenue Next Year
- VRDN N/A
- INMD $3.13
- P/E Ratio
- VRDN N/A
- INMD $9.80
- Revenue Growth
- VRDN N/A
- INMD N/A
- 52 Week Low
- VRDN $11.40
- INMD $14.87
- 52 Week High
- VRDN $27.20
- INMD $26.80
- Technical
- Relative Strength Index (RSI)
- VRDN 36.38
- INMD 49.83
- Support Level
- VRDN $22.40
- INMD $19.11
- Resistance Level
- VRDN $27.20
- INMD $19.85
- Average True Range (ATR)
- VRDN 1.36
- INMD 0.62
- MACD
- VRDN -0.41
- INMD -0.01
- Stochastic Oscillator
- VRDN 6.37
- INMD 37.20
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
About INMD InMode Ltd.
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.